Gilead Seeks Deals as U.S. Hepatitis C Sales May Flatten

  • Drugmaker announces $12 billion added to share repurchase
  • Hepatitis C drugs sell $4.89 billion in fourth quarter

Gilead Sciences Inc. expects U.S. use of its blockbuster hepatitis C treatment to be flat or stable this year as the franchise faces new competition from other drugmakers. The biotechnology firm is on the lookout for acquisition opportunities to sustain growth, executives said.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.